Glenmark Pharmaceuticals is developing a TRPA1 receptor antagonist for pain and respiratory disorders.
The Indian company joins at least four other firms including Hydra Biosciences, Abbott and Janssen that are known to be working in the same ...
Abbott 's TNF alpha-targeting antibody Humira (adalimumab) has been filed in Japan for the additional indication of juvenile idiopathic arthritis (JIA).
The submission is for a subcutaneously injected 40mg/0.8ml prefilled syringe formulation and a ...
NICE, the health technology appraisal institute for England and Wales, has U-turned on previous draft recommendations on biologic treatments for rheumatoid arthritis (RA). Two pieces of final guidance published today now give patients access to more ...
Widening losses at Oxford BioMedica in the first half of 2010 were tempered by positive news on a number of the company's product development programmes.
These included possibilities for accelerating clinical trials with ProSavin, the gene-based ...
A joint meeting on 20 August of two US FDA advisory committees put major roadblocks in the way of Jazz Pharmaceuticals' new drug application (NDA) to sell sodium oxybate as a treatment for fibromyalgia. The panel of outside experts on arthritis ...
